Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295

Reuters2026/08/26 11:24

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Gubra disclosed AbbVie has started a Phase 2 trial of obesity drug candidate ABBV-295, triggering a USD 50 million milestone payment.
Earlier Phase 1 results have already been presented, indicating weight loss potential with acceptable safety and tolerability.
The Phase 2 study will test multiple dosing approaches in adults with obesity or overweight, with efficacy readouts expected later.
ABBV-295 targets amylin, positioning it as a distinct mechanism from GLP-1 or GIP-based weight-loss drugs.
The 2025 license deal leaves Gubra eligible for up to USD 1.875 billion in milestones, plus tiered royalties on global net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gubra A/S published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Gubra earns USD 50 million milestone as AbbVie starts Phase 2 trial of obesity drug ABBV-295

You may also like

Crypto prices